{
  "meta": {
    "title": "30_Immuno_Pharmacology",
    "url": "https://brainandscalpel.vercel.app/30-immuno-pharmacology-14cd823a.html",
    "scrapedAt": "2025-11-30T06:59:52.421Z"
  },
  "questions": [
    {
      "id": 72659,
      "choices": [
        {
          "id": 201668,
          "text": "Adapalene"
        },
        {
          "id": 201669,
          "text": "Tazarotene"
        },
        {
          "id": 201670,
          "text": "Alitretinoin"
        },
        {
          "id": 201671,
          "text": "Bexarotine"
        }
      ],
      "text": "A topical retinoid recently introduced for the treatment of psoriasis is:",
      "unique_key": "Q7566256",
      "question_audio": null,
      "question_video": null,
      "map_id": 34698159,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Tazarotene because it is a topical retinoid specifically approved for the treatment of plaque psoriasis and acne. Tazarotene is a third-generation retinoid that modulates gene expression to reduce keratinocyte proliferation, inflammation, and abnormal differentiation, which are key pathological features of psoriasis. It is available as a gel or cream and is commonly used in combination with corticosteroids to enhance efficacy and minimize irritation. Tazarotene is preferred due to its targeted action on retinoic acid receptors (RARs), particularly RAR-α and RAR-β, making it effective in managing psoriasis while limiting systemic side effects. Incorrect Options: (A) Adapalene: Although it is a third-generation topical retinoid, adapalene is primarily used for the treatment of acne vulgaris rather than psoriasis. Its anti-inflammatory and keratolytic properties make it beneficial for acne, but it is not widely used for psoriasis. (C) Alitretinoin: This is a systemic retinoid primarily indicated for chronic hand eczema and Kaposi’s sarcoma, not for psoriasis. While it has retinoid activity, it is not a first-line or widely accepted topical treatment for psoriasis. (D) Bexarotine: This is a retinoid X receptor (RXR) agonist used specifically for cutaneous T-cell lymphoma (CTCL) rather than psoriasis. Unlike tazarotene, bexarotene does not have significant clinical utility in treating plaque psoriasis.",
      "correct_choice_id": 201669,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75979371700148347/75979371700148347.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75979371700148347/75979371700148347.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72660,
      "choices": [
        {
          "id": 201672,
          "text": "Azathioprine"
        },
        {
          "id": 201673,
          "text": "Mycophenolate mofetil"
        },
        {
          "id": 201674,
          "text": "Methotrexate"
        },
        {
          "id": 201675,
          "text": "Cyclosporine"
        }
      ],
      "text": "Which of the following immunosuppressive agent requires monitoring of renal function on regular basis?",
      "unique_key": "Q8484212",
      "question_audio": null,
      "question_video": null,
      "map_id": 34234946,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Cyclosporine because it is a calcineurin inhibitor that is known for its nephrotoxicity, requiring regular monitoring of renal function (serum creatinine, blood urea nitrogen, and glomerular filtration rate). Cyclosporine exerts its immunosuppressive effects by inhibiting T-cell activation through suppression of interleukin-2 (IL-2) production. However, its nephrotoxic effects arise due to vasoconstriction of renal afferent arterioles, leading to dose-dependent renal impairment. Long-term use can cause chronic nephropathy, hypertension, and electrolyte disturbances, making renal function monitoring essential in patients receiving cyclosporine therapy. Incorrect Options: (A) Azathioprine: This is a purine synthesis inhibitor used for immunosuppression, particularly in organ transplantation and autoimmune diseases. Its primary toxicities include bone marrow suppression (leukopenia, anemia, thrombocytopenia) and hepatotoxicity, but it does not typically cause direct renal damage, so routine renal function monitoring is not required. (B) Mycophenolate mofetil: This agent inhibits inosine monophosphate dehydrogenase (IMPDH), reducing lymphocyte proliferation. Its main adverse effects are gastrointestinal disturbances (diarrhea, nausea) and bone marrow suppression, but it does not cause significant nephrotoxicity. Renal function monitoring is not a standard requirement. (C) Methotrexate: This is a dihydrofolate reductase inhibitor commonly used in autoimmune diseases and cancer. It is mainly associated with hepatotoxicity, pulmonary toxicity, and myelosuppression, but renal toxicity occurs only in high doses due to precipitation of methotrexate in the renal tubules. However, at immunosuppressive doses, regular renal monitoring is not a primary requirement.",
      "correct_choice_id": 201675,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24368341700148361/24368341700148361.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24368341700148361/24368341700148361.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72661,
      "choices": [
        {
          "id": 201676,
          "text": "Adalimumab"
        },
        {
          "id": 201677,
          "text": "Etanercept"
        },
        {
          "id": 201678,
          "text": "Infliximab"
        },
        {
          "id": 201679,
          "text": "Abciximab"
        }
      ],
      "text": "All of the following are tumor necrosis factor blocking agent, except:",
      "unique_key": "Q4194069",
      "question_audio": null,
      "question_video": null,
      "map_id": 34623824,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Abciximab because it is not a tumor necrosis factor (TNF) blocking agent. Instead, abciximab is a glycoprotein IIb/IIIa receptor antagonist used as an antiplatelet agent to prevent thrombosis during percutaneous coronary interventions (PCI), such as angioplasty. It works by inhibiting platelet aggregation rather than blocking TNF-?, which is a pro-inflammatory cytokine involved in autoimmune diseases. Since abciximab has no role in TNF inhibition, it does not belong in the same category as the other drugs listed. Incorrect Options: (A) Adalimumab: This is a fully human monoclonal antibody that binds to TNF-?, preventing it from interacting with its receptors. It is used in autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. (B) Etanercept: This is a fusion protein consisting of a TNF receptor linked to the Fc portion of IgG1. It acts as a decoy receptor, binding to TNF-? and preventing its pro-inflammatory effects. It is used in rheumatoid arthritis, psoriasis, and ankylosing spondylitis. (C) Infliximab: This is a chimeric monoclonal antibody (mouse-human) that directly binds TNF-?. It is commonly used in autoimmune disorders like inflammatory bowel disease (IBD), rheumatoid arthritis, and psoriatic arthritis.",
      "correct_choice_id": 201679,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38638771700148402/38638771700148402.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38638771700148402/38638771700148402.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72662,
      "choices": [
        {
          "id": 201680,
          "text": "HIV related neuropathy"
        },
        {
          "id": 201681,
          "text": "Erythema nodosum leprosum"
        },
        {
          "id": 201682,
          "text": "HIV related oral ulcer"
        },
        {
          "id": 201683,
          "text": "Behcet’s disease"
        }
      ],
      "text": "Thalidomide is not used in:",
      "unique_key": "Q6427842",
      "question_audio": null,
      "question_video": null,
      "map_id": 34000382,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) HIV-related neuropathy because thalidomide is not a standard or approved treatment for this condition. HIV-related neuropathy, particularly distal symmetrical polyneuropathy (DSP), is commonly managed with medications such as gabapentinoids (gabapentin, pregabalin), tricyclic antidepressants, selective serotonin-norepinephrine reuptake inhibitors (SNRIs), or opioids in severe cases. Thalidomide, while having immunomodulatory and anti-inflammatory properties, is not indicated for managing neuropathic pain in HIV patients due to its neurotoxic effects, which could potentially worsen neuropathy. Incorrect Options: (B) Erythema nodosum leprosum (ENL): This is a severe inflammatory complication of leprosy, characterized by painful nodules, fever, and systemic symptoms. Thalidomide is FDA-approved for the treatment of ENL due to its potent anti-inflammatory and immunomodulatory effects. It inhibits TNF-?, which plays a critical role in ENL pathogenesis. (C) HIV-related oral ulcers: Thalidomide has been studied and used in cases of severe or refractory oral ulcers in HIV patients. Its anti-inflammatory and immunomodulatory effects help reduce ulceration and promote healing, particularly when standard treatments fail. (D) Behçet’s disease: Thalidomide has been used off-label for treating Behçet’s disease, particularly for severe oral and genital ulcers that are resistant to conventional therapies. Its ability to suppress excessive immune activation and TNF-? production makes it beneficial in managing this autoimmune condition.",
      "correct_choice_id": 201680,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12791301700148421/12791301700148421.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12791301700148421/12791301700148421.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72663,
      "choices": [
        {
          "id": 201684,
          "text": "It has more anti tumor effect than immunosuppressant effect"
        },
        {
          "id": 201685,
          "text": "It is a prodrug"
        },
        {
          "id": 201686,
          "text": "It selectively affects differentiation of B cells"
        },
        {
          "id": 201687,
          "text": "It is a pyrimidine antimetabolite"
        }
      ],
      "text": "True about azathioprine is:",
      "unique_key": "Q1278240",
      "question_audio": null,
      "question_video": null,
      "map_id": 34331083,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) It is a prodrug because azathioprine is metabolized in the body to its active form, 6-mercaptopurine (6-MP). This conversion occurs primarily in the liver and is facilitated by enzymes such as glutathione transferase. 6-MP is further metabolized to thioinosinic acid, which inhibits purine nucleotide synthesis, ultimately suppressing the proliferation of rapidly dividing immune cells like T and B lymphocytes. This makes azathioprine a potent immunosuppressant commonly used in organ transplantation, autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis), and inflammatory bowel disease (IBD). Incorrect Options: (A) It has more antitumor effect than immunosuppressant effect: This is incorrect because azathioprine is primarily used for immunosuppression, not as an antitumor agent. While it does have some antiproliferative effects due to its inhibition of DNA and RNA synthesis, it is not a primary chemotherapy drug and is rarely used in cancer treatment. (C) It selectively affects differentiation of B cells: Azathioprine suppresses both T and B lymphocytes by interfering with purine metabolism. It does not selectively affect B cells; instead, it broadly inhibits immune cell proliferation, reducing overall immune response. (D) It is a pyrimidine antimetabolite: This is incorrect because azathioprine is a purine antimetabolite, not a pyrimidine analog. It specifically interferes with purine synthesis, unlike drugs like 5-fluorouracil or cytarabine, which target pyrimidine metabolism.",
      "correct_choice_id": 201685,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58337661700148441/58337661700148441.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58337661700148441/58337661700148441.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72664,
      "choices": [
        {
          "id": 201688,
          "text": "CD20"
        },
        {
          "id": 201689,
          "text": "EGFR"
        },
        {
          "id": 201690,
          "text": "VEGF"
        },
        {
          "id": 201691,
          "text": "IL-2"
        }
      ],
      "text": "Rituximab is antibody against",
      "unique_key": "Q6340367",
      "question_audio": null,
      "question_video": null,
      "map_id": 34279320,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) CD20 because rituximab is a monoclonal antibody that specifically targets the CD20 antigen, which is expressed on the surface of B lymphocytes. By binding to CD20, rituximab induces B-cell depletion through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-mediated cytotoxicity (CMC), and direct apoptosis. This makes rituximab highly effective in the treatment of B-cell malignancies (such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia) and autoimmune diseases (such as rheumatoid arthritis, pemphigus vulgaris, and immune thrombocytopenic purpura). Incorrect Options: (B) EGFR (Epidermal Growth Factor Receptor): This is incorrect because EGFR-targeting monoclonal antibodies include cetuximab and panitumumab, which are used in cancers such as colorectal carcinoma and non-small cell lung cancer (NSCLC). Rituximab does not act on EGFR. (C) VEGF (Vascular Endothelial Growth Factor): This is incorrect because VEGF is targeted by bevacizumab, which is used to inhibit angiogenesis in cancers such as colorectal cancer, glioblastoma, and renal cell carcinoma. Rituximab has no role in VEGF inhibition. (D) IL-2 (Interleukin-2): This is incorrect because IL-2 is targeted by drugs like daclizumab and basiliximab, which are used in transplant immunosuppression to prevent organ rejection. Rituximab does not interfere with IL-2 signaling.",
      "correct_choice_id": 201688,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55187181700148457/55187181700148457.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55187181700148457/55187181700148457.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72665,
      "choices": [
        {
          "id": 201692,
          "text": "Monoclonal antibody against VEGF"
        },
        {
          "id": 201693,
          "text": "Anti-IL-2 monoclonal antibody"
        },
        {
          "id": 201694,
          "text": "Monoclonal antibody against FGFR"
        },
        {
          "id": 201695,
          "text": "Monoclonal antibody against EGFR"
        }
      ],
      "text": "Bevacizumab is:",
      "unique_key": "Q7841018",
      "question_audio": null,
      "question_video": null,
      "map_id": 34526429,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Monoclonal antibody against VEGF because bevacizumab is a humanized monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF). VEGF plays a critical role in angiogenesis (formation of new blood vessels), which is essential for tumor growth and metastasis. By inhibiting VEGF, bevacizumab prevents blood vessel formation, thereby restricting oxygen and nutrient supply to tumors, leading to tumor shrinkage and inhibition of growth. Bevacizumab is used in the treatment of various cancers, including colorectal cancer, lung cancer, renal cell carcinoma, and glioblastoma, and is also used in ophthalmology for conditions like age-related macular degeneration (AMD) to reduce pathological angiogenesis. Incorrect Options: (B) Anti-IL-2 monoclonal antibody: This is incorrect because IL-2 (Interleukin-2) is targeted by monoclonal antibodies like daclizumab and basiliximab, which are used in organ transplantation to prevent rejection by inhibiting T-cell activation. Bevacizumab does not affect IL-2 pathways. (C) Monoclonal antibody against FGFR (Fibroblast Growth Factor Receptor): This is incorrect because FGFR-targeting agents, such as pemigatinib and erdafitinib, are used in cancers like cholangiocarcinoma. Bevacizumab does not interact with FGFR. (D) Monoclonal antibody against EGFR (Epidermal Growth Factor Receptor): This is incorrect because EGFR is targeted by monoclonal antibodies like cetuximab and panitumumab, which are used in colorectal cancer and head and neck cancers. Bevacizumab does not inhibit EGFR signaling.",
      "correct_choice_id": 201692,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58539951700148469/58539951700148469.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58539951700148469/58539951700148469.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72666,
      "choices": [
        {
          "id": 201696,
          "text": "CD 25"
        },
        {
          "id": 201697,
          "text": "CD 11a"
        },
        {
          "id": 201698,
          "text": "TNF"
        },
        {
          "id": 201699,
          "text": "IL-2"
        }
      ],
      "text": "Basiliximab acts by antagonism against",
      "unique_key": "Q5845082",
      "question_audio": null,
      "question_video": null,
      "map_id": 34524828,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) CD25 because basiliximab is a monoclonal antibody that specifically targets the CD25 (α-subunit of the IL-2 receptor), which is expressed on activated T lymphocytes. By blocking CD25, basiliximab prevents interleukin-2 (IL-2) from binding to its receptor, thereby inhibiting T-cell proliferation and activation. This immunosuppressive action makes basiliximab particularly useful in preventing acute organ rejection in kidney transplantation. It is commonly used as part of induction therapy in transplant recipients to reduce early immune responses against the transplanted organ. Incorrect Options: (B) CD11a: This is incorrect because CD11a is targeted by efalizumab, which was used to treat psoriasis by inhibiting leukocyte adhesion but was withdrawn due to severe side effects. Basiliximab does not act on CD11a. (C) TNF (Tumor Necrosis Factor): This is incorrect because TNF-α is targeted by monoclonal antibodies such as infliximab, adalimumab, and etanercept, which are used in autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Basiliximab does not inhibit TNF-α (D) IL-2: This is incorrect because while basiliximab indirectly affects IL-2 signaling, it does so by blocking CD25 (IL-2 receptor α-subunit), not by directly inhibiting IL-2 itself. Drugs like daclizumab also work similarly by targeting CD25.",
      "correct_choice_id": 201696,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35887181700148480/35887181700148480.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35887181700148480/35887181700148480.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72667,
      "choices": [
        {
          "id": 201700,
          "text": "Cyclophosphamide"
        },
        {
          "id": 201701,
          "text": "Cyclosporine"
        },
        {
          "id": 201702,
          "text": "Etanercept"
        },
        {
          "id": 201703,
          "text": "Sirolimus"
        }
      ],
      "text": "Which of the following is a calcineurin inhibitor?",
      "unique_key": "Q1039619",
      "question_audio": null,
      "question_video": null,
      "map_id": 34260553,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Cyclosporine because it is a calcineurin inhibitor that works by blocking the activation of T cells through inhibition of interleukin-2 (IL-2) production. Cyclosporine binds to cyclophilin, forming a complex that inhibits calcineurin, a key enzyme required for the activation of nuclear factor of activated T-cells (NFAT). NFAT is responsible for IL-2 transcription, which is essential for T-cell proliferation. By suppressing IL-2 production, cyclosporine is widely used as an immunosuppressant in organ transplantation, autoimmune diseases (such as rheumatoid arthritis), and graft-versus-host disease. However, cyclosporine is nephrotoxic, requiring regular renal function monitoring. Incorrect Options: (A) Cyclophosphamide: This is incorrect because cyclophosphamide is an alkylating agent, not a calcineurin inhibitor. It works by cross-linking DNA, leading to cell cycle arrest and apoptosis, mainly affecting rapidly dividing immune cells. It is used in conditions such as systemic lupus erythematosus (SLE), vasculitis, and certain cancers. (C) Etanercept: This is incorrect because etanercept is a TNF-? inhibitor, not a calcineurin inhibitor. It acts as a decoy receptor that binds TNF-?, preventing it from interacting with its cellular receptors. It is used in autoimmune diseases like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. (D) Sirolimus: This is incorrect because sirolimus (rapamycin) is an mTOR inhibitor, not a calcineurin inhibitor. It works by binding to FKBP-12 and inhibiting mTOR (mammalian target of rapamycin), thereby blocking T-cell proliferation in response to IL-2. Unlike cyclosporine, sirolimus is not nephrotoxic and is often used in transplant patients to reduce renal toxicity.",
      "correct_choice_id": 201701,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11344971700148492/11344971700148492.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11344971700148492/11344971700148492.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72668,
      "choices": [
        {
          "id": 201704,
          "text": "Certolizumab"
        },
        {
          "id": 201705,
          "text": "Rifampicin"
        },
        {
          "id": 201706,
          "text": "Omalizumab"
        },
        {
          "id": 201707,
          "text": "Canakinumab"
        }
      ],
      "text": "Anti IgE monoclonal antibody is:",
      "unique_key": "Q1320418",
      "question_audio": null,
      "question_video": null,
      "map_id": 34936831,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Omalizumab because it is a monoclonal antibody that specifically targets immunoglobulin E (IgE). By binding to free IgE, omalizumab prevents its interaction with the FcεRI receptor on mast cells and basophils, thereby reducing the release of inflammatory mediators like histamine, leukotrienes, and prostaglandins. This mechanism helps in reducing allergic inflammation and is particularly useful in the treatment of moderate to severe allergic asthma and chronic spontaneous urticaria. Omalizumab is administered subcutaneously and is used in patients who do not respond well to conventional asthma therapies, such as inhaled corticosteroids and β2-agonists. Incorrect Options: (A) Certolizumab: This is incorrect because certolizumab pegol is an anti-TNF-α monoclonal antibody, not an anti-IgE agent. It is used in rheumatoid arthritis, Crohn’s disease, and psoriatic arthritis. Unlike omalizumab, it does not target allergic pathways. (B) Rifampicin: This is incorrect because rifampicin is an antibiotic, not a monoclonal antibody. It works by inhibiting bacterial RNA polymerase, making it effective against tuberculosis, leprosy, and certain bacterial infections. It has no role in IgE-mediated allergic conditions. (D) Canakinumab: This is incorrect because canakinumab is an IL-1β inhibitor, not an anti-IgE monoclonal antibody. It is used in autoinflammatory conditions such as cryopyrin-associated periodic syndromes (CAPS) and systemic juvenile idiopathic arthritis (sJIA). It does not interfere with IgE or allergic pathways.",
      "correct_choice_id": 201706,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62598831700148510/62598831700148510.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62598831700148510/62598831700148510.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72669,
      "choices": [
        {
          "id": 201708,
          "text": "Cisplatin"
        },
        {
          "id": 201709,
          "text": "Tacrolimus"
        },
        {
          "id": 201710,
          "text": "Mycophenolate mofetil"
        },
        {
          "id": 201711,
          "text": "Naproxen"
        }
      ],
      "text": "Which of the following drugs does not cause renal toxicity",
      "unique_key": "Q1369001",
      "question_audio": null,
      "question_video": null,
      "map_id": 34371907,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Mycophenolate mofetil because it does not cause renal toxicity. Mycophenolate mofetil (MMF) is an immunosuppressant that works by inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for purine synthesis in lymphocytes. By selectively blocking purine synthesis, MMF prevents T and B cell proliferation without significantly affecting other rapidly dividing cells. It is widely used in organ transplantation to prevent rejection and in autoimmune diseases like lupus nephritis and rheumatoid arthritis. Unlike other immunosuppressants such as tacrolimus and cyclosporine, MMF is not nephrotoxic, making it a preferred agent in transplant recipients with pre-existing kidney disease. Incorrect Options: (A) Cisplatin: This is incorrect because cisplatin is highly nephrotoxic. It is a platinum-based chemotherapy agent that causes acute tubular necrosis (ATN) and chronic kidney injury by generating reactive oxygen species and damaging renal tubular cells. Patients receiving cisplatin require adequate hydration and nephroprotective measures (e.g., amifostine) to minimize kidney damage. (B) Tacrolimus: This is incorrect because tacrolimus is a calcineurin inhibitor that causes nephrotoxicity. It induces vasoconstriction of the afferent arteriole, leading to renal ischemia and chronic kidney disease. Regular monitoring of serum creatinine and tacrolimus levels is required to prevent toxicity in transplant patients. (D) Naproxen: This is incorrect because naproxen, like other NSAIDs, can cause renal toxicity. NSAIDs inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which in turn leads to afferent arteriole vasoconstriction and reduced renal perfusion. Chronic NSAID use can cause acute kidney injury (AKI) and interstitial nephritis, especially in patients with pre-existing kidney disease.",
      "correct_choice_id": 201710,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41356751700148520/41356751700148520.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41356751700148520/41356751700148520.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72670,
      "choices": [
        {
          "id": 201712,
          "text": "Cyclophosphamide"
        },
        {
          "id": 201713,
          "text": "Azathioprine"
        },
        {
          "id": 201714,
          "text": "Cyclosporine"
        },
        {
          "id": 201715,
          "text": "Cystosine arabinoside"
        }
      ],
      "text": "Which of the following immuno-suppressive agents acts mainly by inhibiting helper T-cells?",
      "unique_key": "Q2366506",
      "question_audio": null,
      "question_video": null,
      "map_id": 34166041,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Cyclosporine because it primarily acts by inhibiting helper T-cells (CD4+ T-cells). Cyclosporine is a calcineurin inhibitor that binds to cyclophilin, forming a complex that inhibits calcineurin, an essential enzyme required for the activation of nuclear factor of activated T-cells (NFAT). NFAT is necessary for the transcription of interleukin-2 (IL-2), a key cytokine that stimulates T-cell proliferation. By blocking IL-2 production, cyclosporine prevents the activation and expansion of helper T-cells, thereby suppressing the immune response. It is widely used in organ transplantation, autoimmune diseases (such as rheumatoid arthritis and psoriasis), and graft-versus-host disease (GVHD). However, cyclosporine is nephrotoxic, requiring regular monitoring of renal function. Incorrect Options: (A) Cyclophosphamide: This is incorrect because cyclophosphamide is an alkylating agent that acts by cross-linking DNA, leading to the apoptosis of rapidly dividing cells, including both T and B lymphocytes. It is used in autoimmune diseases (such as lupus nephritis and vasculitis) and some cancers, but it does not selectively inhibit helper T-cells like cyclosporine. (B) Azathioprine: This is incorrect because azathioprine is a purine analog that inhibits DNA synthesis, affecting both T and B lymphocytes, especially during their proliferation. It is commonly used as an immunosuppressant in organ transplantation and autoimmune diseases, but its mechanism does not specifically target helper T-cells. (D) Cytosine arabinoside (Cytarabine): This is incorrect because cytarabine is a cytotoxic antimetabolite used in the treatment of leukemia and lymphoma. It works by inhibiting DNA polymerase, leading to apoptosis in rapidly dividing cells, but it is not an immunosuppressant specifically targeting helper T-cells.",
      "correct_choice_id": 201714,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55105951700148534/55105951700148534.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55105951700148534/55105951700148534.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72671,
      "choices": [
        {
          "id": 201716,
          "text": "Erythromycin"
        },
        {
          "id": 201717,
          "text": "Itraconazole"
        },
        {
          "id": 201718,
          "text": "Danazol"
        },
        {
          "id": 201719,
          "text": "Rifampicin"
        }
      ],
      "text": "Tacrolimus level is increased by all except:",
      "unique_key": "Q5889609",
      "question_audio": null,
      "question_video": null,
      "map_id": 34141129,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Rifampicin because rifampicin decreases tacrolimus levels by inducing the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is primarily metabolized in the liver by CYP3A4, and rifampicin is a strong inducer of this enzyme. This induction leads to increased metabolism and clearance of tacrolimus, significantly reducing its plasma concentration. In transplant patients, rifampicin use can lead to subtherapeutic tacrolimus levels, increasing the risk of organ rejection. Incorrect Options: (A) Erythromycin: This is incorrect because erythromycin increases tacrolimus levels by inhibiting CYP3A4, leading to reduced metabolism and prolonged drug exposure. This can result in increased toxicity, including nephrotoxicity, neurotoxicity, and hypertension. (B) Itraconazole: This is incorrect because itraconazole is a potent CYP3A4 inhibitor, which reduces the metabolism of tacrolimus, leading to higher drug levels. Patients taking itraconazole and tacrolimus concurrently require dose adjustments and close monitoring to avoid toxicity. (C) Danazol: This is incorrect because danazol inhibits CYP3A4, resulting in increased tacrolimus levels. It can lead to excessive immunosuppression and increased risk of adverse effects, such as renal dysfunction and hypertension.",
      "correct_choice_id": 201719,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54806711700148580/54806711700148580.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54806711700148580/54806711700148580.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72672,
      "choices": [
        {
          "id": 201720,
          "text": "Ifosfamide"
        },
        {
          "id": 201721,
          "text": "Infliximab"
        },
        {
          "id": 201722,
          "text": "Etanercept"
        },
        {
          "id": 201723,
          "text": "Adalimumab"
        }
      ],
      "text": "All are TNF-alpha antagonist used in rheumatoid arthritis except:",
      "unique_key": "Q7145980",
      "question_audio": null,
      "question_video": null,
      "map_id": 34978826,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Ifosfamide because it is not a TNF-α antagonist and has no role in the treatment of rheumatoid arthritis (RA). Ifosfamide is an alkylating agent that works by cross-linking DNA, leading to cell cycle arrest and apoptosis. It is primarily used in the treatment of various cancers, including sarcomas, lymphomas, and testicular cancer. Unlike TNF-α inhibitors, ifosfamide does not modulate immune responses or inflammation in autoimmune diseases like RA. Incorrect Options: (B) Infliximab: This is incorrect because infliximab is a TNF-α antagonist used in rheumatoid arthritis. It is a chimeric monoclonal antibody (human-mouse) that binds to TNF-α, preventing its interaction with TNF receptors and thereby reducing inflammation and joint damage in RA. (C) Etanercept: This is incorrect because etanercept is a TNF-α inhibitor used in rheumatoid arthritis. It is a fusion protein composed of the TNF receptor linked to the Fc portion of IgG1, acting as a decoy receptor that binds TNF-α and prevents its inflammatory effects. (D) Adalimumab: This is incorrect because adalimumab is a fully human monoclonal antibody against TNF-α. It neutralizes TNF-α activity and is widely used in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease (IBD).",
      "correct_choice_id": 201720,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52423751700148601/52423751700148601.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52423751700148601/52423751700148601.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72673,
      "choices": [
        {
          "id": 201724,
          "text": "Transtuzumab"
        },
        {
          "id": 201725,
          "text": "Ibritumomab"
        },
        {
          "id": 201726,
          "text": "Rituximab"
        },
        {
          "id": 201727,
          "text": "Imatinib"
        }
      ],
      "text": "The only FDA approved radioactive antibody that be used for treatment of lymphoma",
      "unique_key": "Q7165995",
      "question_audio": null,
      "question_video": null,
      "map_id": 34925160,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Ibritumomab because it is the only FDA-approved radioactive monoclonal antibody used for the treatment of lymphoma. Ibritumomab targets CD20, a surface antigen present on B-cells, making it effective in B-cell non-Hodgkin’s lymphoma (NHL). It is conjugated to a radioactive isotope (Yttrium-90 or Indium-111), which allows it to deliver targeted radiation therapy directly to malignant B-cells while sparing surrounding healthy tissues. This radioimmunotherapy is particularly useful in patients with relapsed or refractory B-cell lymphoma who have not responded to conventional treatments. Incorrect Options: (A) Trastuzumab: This is incorrect because trastuzumab is a monoclonal antibody against HER2 (human epidermal growth factor receptor 2) and is primarily used in the treatment of HER2-positive breast cancer and gastric cancer. It does not target lymphoma and is not a radioactive antibody. (C) Rituximab: This is incorrect because rituximab is an anti-CD20 monoclonal antibody used in the treatment of B-cell lymphomas, rheumatoid arthritis, and autoimmune diseases. However, it is not conjugated with a radioactive isotope, distinguishing it from ibritumomab. (D) Imatinib: This is incorrect because imatinib is a tyrosine kinase inhibitor (TKI), not a monoclonal antibody. It is used in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) by targeting the BCR-ABL fusion protein and c-KIT receptor tyrosine kinase. It has no role in treating lymphoma with radioimmunotherapy.",
      "correct_choice_id": 201725,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36201421700148633/36201421700148633.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36201421700148633/36201421700148633.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72674,
      "choices": [
        {
          "id": 201728,
          "text": "DNA and RNA synthesis"
        },
        {
          "id": 201729,
          "text": "Anti-lymphocyte antibody formation"
        },
        {
          "id": 201730,
          "text": "T-cell proliferation"
        },
        {
          "id": 201731,
          "text": "All of the above"
        }
      ],
      "text": "Tacrolimus acts by inhibiting:",
      "unique_key": "Q6487133",
      "question_audio": null,
      "question_video": null,
      "map_id": 34875509,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) T-cell proliferation because tacrolimus is a calcineurin inhibitor that specifically prevents T-cell activation and proliferation. Tacrolimus binds to FK-binding protein 12 (FKBP-12), forming a complex that inhibits calcineurin, an enzyme necessary for dephosphorylation and activation of nuclear factor of activated T-cells (NFAT). NFAT is required for the transcription of interleukin-2 (IL-2), a crucial cytokine for T-cell proliferation. By blocking IL-2 production, tacrolimus effectively suppresses the immune response, making it useful in organ transplantation and autoimmune diseases to prevent rejection and inflammation. Incorrect Options: (A) DNA and RNA synthesis: This is incorrect because tacrolimus does not directly inhibit DNA or RNA synthesis. Unlike antimetabolite drugs such as azathioprine or mycophenolate mofetil, which interfere with nucleotide synthesis, tacrolimus specifically blocks T-cell signaling and activation without affecting DNA or RNA synthesis. (B) Anti-lymphocyte antibody formation: This is incorrect because tacrolimus does not inhibit the production of anti-lymphocyte antibodies. Some immunosuppressive therapies, such as anti-thymocyte globulin (ATG) and rituximab, target lymphocyte antibodies, but tacrolimus works by blocking IL-2-dependent T-cell activation. (D) All of the above: This is incorrect because tacrolimus does not act on DNA/RNA synthesis or antibody formation. It primarily inhibits T-cell activation and proliferation by disrupting calcineurin signaling, making option (C) the most accurate choice.",
      "correct_choice_id": 201730,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42936411700148654/42936411700148654.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42936411700148654/42936411700148654.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72675,
      "choices": [
        {
          "id": 201732,
          "text": "Post- transplant lymphoproliferative disorders"
        },
        {
          "id": 201733,
          "text": "Hypotension"
        },
        {
          "id": 201734,
          "text": "Nephrotoxicity"
        },
        {
          "id": 201735,
          "text": "Tremors"
        }
      ],
      "text": "All of the following are side effects of cyclosporine except:",
      "unique_key": "Q5060185",
      "question_audio": null,
      "question_video": null,
      "map_id": 34877495,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Hypotension because cyclosporine is actually more commonly associated with hypertension rather than hypotension. Cyclosporine, a calcineurin inhibitor, causes vasoconstriction and sodium retention, leading to an increase in blood pressure. It can also contribute to renal dysfunction, further worsening hypertension. Due to this, regular blood pressure monitoring is essential in patients receiving cyclosporine therapy. Incorrect Options: (A) Post-transplant lymphoproliferative disorders (PTLD): This is incorrect because cyclosporine increases the risk of PTLD, a serious complication in transplant recipients. PTLD is associated with uncontrolled B-cell proliferation, often triggered by Epstein-Barr Virus (EBV) infection, due to the intense immunosuppression caused by drugs like cyclosporine. (C) Nephrotoxicity: This is incorrect because nephrotoxicity is one of the most well-known and serious adverse effects of cyclosporine. It causes renal vasoconstriction, leading to reduced glomerular filtration rate (GFR) and potentially progressing to chronic kidney disease (CKD) with prolonged use. (D) Tremors: This is incorrect because cyclosporine can cause neurotoxicity, manifesting as tremors, headaches, paresthesia, and, in severe cases, seizures. Tremors are dose-dependent and are commonly observed in patients receiving higher doses of cyclosporine.",
      "correct_choice_id": 201733,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4308371700148722/4308371700148722.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4308371700148722/4308371700148722.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72676,
      "choices": [
        {
          "id": 201736,
          "text": "TNF alpha"
        },
        {
          "id": 201737,
          "text": "TGF beta"
        },
        {
          "id": 201738,
          "text": "IL-2"
        },
        {
          "id": 201739,
          "text": "IL-6"
        }
      ],
      "text": "Etanercept used in rheumatoid arthritis act by the inhibition of:",
      "unique_key": "Q8810342",
      "question_audio": null,
      "question_video": null,
      "map_id": 34336121,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) TNF-alpha because etanercept is a TNF-alpha inhibitor used in the treatment of rheumatoid arthritis (RA) and other autoimmune diseases. Etanercept is a fusion protein consisting of the extracellular domain of the TNF receptor fused to the Fc portion of human IgG1. It works by binding to TNF-alpha and preventing it from interacting with its receptor, thereby reducing inflammation, joint damage, and disease progression in RA. TNF-alpha is a pro-inflammatory cytokine that plays a key role in the pathogenesis of RA by promoting synovial inflammation, cartilage destruction, and bone erosion. Incorrect Options: (B) TGF-beta: This is incorrect because TGF-beta (Transforming Growth Factor-beta) is an anti-inflammatory cytokine that regulates immune function and tissue repair. Etanercept does not inhibit TGF-beta, as blocking this cytokine could potentially worsen inflammation rather than reduce it. (C) IL-2: This is incorrect because IL-2 (Interleukin-2) is mainly involved in T-cell proliferation and immune activation. IL-2 inhibitors, such as basiliximab and daclizumab, are used in transplant medicine to prevent organ rejection, but etanercept does not act on IL-2. (D) IL-6: This is incorrect because IL-6 is a pro-inflammatory cytokine involved in RA, but etanercept does not directly inhibit IL-6. Instead, tocilizumab, an IL-6 receptor antagonist, is used for RA treatment in patients who do not respond to TNF-alpha inhibitors.",
      "correct_choice_id": 201736,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/32975791700148740/32975791700148740.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/32975791700148740/32975791700148740.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72677,
      "choices": [
        {
          "id": 201740,
          "text": "Methotrexate"
        },
        {
          "id": 201741,
          "text": "Adriamycin"
        },
        {
          "id": 201742,
          "text": "Vincristine"
        },
        {
          "id": 201743,
          "text": "Cyclophosphamide"
        }
      ],
      "text": "Which of the following antineoplastic and immunosuppressant drugs is a dihydrofolate reductase inhibitor?",
      "unique_key": "Q6431445",
      "question_audio": null,
      "question_video": null,
      "map_id": 34877603,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Methotrexate because it is a dihydrofolate reductase (DHFR) inhibitor that functions as both an antineoplastic and immunosuppressant drug. Methotrexate works by competitively inhibiting DHFR, an enzyme essential for the conversion of dihydrofolate (DHF) to tetrahydrofolate (THF). THF is required for the synthesis of purines and thymidylate, which are crucial for DNA and RNA production. By blocking this pathway, methotrexate prevents cell replication, particularly in rapidly dividing cells, making it effective in the treatment of cancers (such as leukemia, lymphoma, and choriocarcinoma) and autoimmune diseases (such as rheumatoid arthritis and psoriasis). Incorrect Options: (B) Adriamycin (Doxorubicin): This is incorrect because doxorubicin is an anthracycline antibiotic that works by intercalating DNA and inhibiting topoisomerase II, leading to DNA strand breaks and apoptosis. It is used in breast cancer, lymphomas, and sarcomas, but it does not inhibit DHFR. (C) Vincristine: This is incorrect because vincristine is a vinca alkaloid that works by inhibiting microtubule polymerization during mitosis, thereby blocking cell division. It is commonly used in hematologic malignancies (e.g., leukemias, lymphomas) and solid tumors, but it does not affect folate metabolism or DHFR. (D) Cyclophosphamide: This is incorrect because cyclophosphamide is an alkylating agent that works by cross-linking DNA strands, leading to cell cycle arrest and apoptosis. It is used in cancers such as lymphoma, leukemia, and breast cancer, as well as in immunosuppressive therapy for autoimmune diseases, but it does not act on DHFR.",
      "correct_choice_id": 201740,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24165521700148751/24165521700148751.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24165521700148751/24165521700148751.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72678,
      "choices": [
        {
          "id": 201744,
          "text": "Nephrotoxicity"
        },
        {
          "id": 201745,
          "text": "Bone marrow suppression"
        },
        {
          "id": 201746,
          "text": "Hypertension"
        },
        {
          "id": 201747,
          "text": "Hirsutism"
        }
      ],
      "text": "Side effects of cyclosporine are all except:",
      "unique_key": "Q8100471",
      "question_audio": null,
      "question_video": null,
      "map_id": 34218100,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Bone marrow suppression because cyclosporine does not typically cause significant bone marrow suppression. Unlike other immunosuppressants such as azathioprine, mycophenolate mofetil, or methotrexate, which inhibit DNA synthesis and affect rapidly dividing cells in the bone marrow, cyclosporine works by inhibiting calcineurin, leading to reduced IL-2 production and T-cell activation suppression. While it has immunosuppressive effects, it does not directly inhibit bone marrow function, making bone marrow suppression an unlikely side effect. Incorrect Options: (A) Nephrotoxicity: This is incorrect because nephrotoxicity is one of the most serious and common side effects of cyclosporine. It occurs due to vasoconstriction of renal arterioles, leading to reduced glomerular filtration rate (GFR) and chronic kidney injury with prolonged use. Patients on cyclosporine require regular renal function monitoring. (C) Hypertension: This is incorrect because cyclosporine frequently causes hypertension due to renal vasoconstriction, sodium retention, and increased sympathetic activity. Many patients require antihypertensive medications such as calcium channel blockers to manage this side effect. (D) Hirsutism: This is incorrect because hirsutism (excessive hair growth) is a well-known side effect of cyclosporine. It occurs due to increased androgenic activity and is particularly noticeable in female patients, causing cosmetic concerns.",
      "correct_choice_id": 201745,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3012431700148763/3012431700148763.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3012431700148763/3012431700148763.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72679,
      "choices": [
        {
          "id": 201748,
          "text": "Immunoglobulin antibody"
        },
        {
          "id": 201749,
          "text": "Non-depolarizing muscle relaxant"
        },
        {
          "id": 201750,
          "text": "Macrolide antibiotic"
        },
        {
          "id": 201751,
          "text": "Opioid anesthetic"
        }
      ],
      "text": "FK 506 is a type of :",
      "unique_key": "Q5780669",
      "question_audio": null,
      "question_video": null,
      "map_id": 34766502,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Macrolide antibiotic because FK 506 (Tacrolimus) is a macrolide-derived immunosuppressant. Although tacrolimus is structurally related to macrolide antibiotics (like erythromycin), it does not have significant antibacterial activity. Instead, it works by binding to FKBP-12 (FK-binding protein), which then inhibits calcineurin, a key enzyme required for T-cell activation and IL-2 production. This makes tacrolimus highly effective in preventing organ transplant rejection and treating autoimmune diseases such as atopic dermatitis and severe rheumatoid arthritis. Incorrect Options: (A) Immunoglobulin antibody: This is incorrect because tacrolimus is a small molecule drug, not an antibody. Immunoglobulin-based therapies, such as rituximab (anti-CD20) or basiliximab (anti-CD25), work through monoclonal antibody-mediated immune modulation, which is different from the mechanism of FK 506. (B) Non-depolarizing muscle relaxant: This is incorrect because non-depolarizing muscle relaxants, such as rocuronium and vecuronium, work by blocking acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis. Tacrolimus does not act on the neuromuscular system. (D) Opioid anesthetic: This is incorrect because opioids like fentanyl and morphine act on mu-opioid receptors in the central nervous system, producing analgesia and sedation. Tacrolimus has no opioid activity and is not used for anesthesia or pain management.",
      "correct_choice_id": 201750,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67087531700148775/67087531700148775.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67087531700148775/67087531700148775.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72680,
      "choices": [
        {
          "id": 201752,
          "text": "Abciximab – antiplatelet"
        },
        {
          "id": 201753,
          "text": "Rituximab – rheumatoid arthritis"
        },
        {
          "id": 201754,
          "text": "Transtuzumab – her2/neu +ve breast carcinoma"
        },
        {
          "id": 201755,
          "text": "Palivizumab – psoriasis"
        }
      ],
      "text": "Which of the following pairs are incorrectly matched:",
      "unique_key": "Q1439718",
      "question_audio": null,
      "question_video": null,
      "map_id": 34839105,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Palivizumab – Psoriasis, because palivizumab is not used for psoriasis. Instead, palivizumab is a monoclonal antibody against respiratory syncytial virus (RSV) fusion protein (F protein). It is primarily used for the prevention of RSV infections in high-risk infants, such as premature babies or those with congenital heart or lung disease. Palivizumab does not have any role in autoimmune skin conditions like psoriasis, making this pairing incorrect. Incorrect Options: (A) Abciximab – Antiplatelet: This is correct because abciximab is a glycoprotein IIb/IIIa receptor antagonist that prevents platelet aggregation. It is used primarily in percutaneous coronary interventions (PCI) to reduce the risk of thrombosis and myocardial infarction. (B) Rituximab – Rheumatoid Arthritis: This is correct because rituximab is a monoclonal antibody against CD20, which depletes B cells and reduces autoimmune inflammation. It is used in rheumatoid arthritis (RA) and B-cell lymphomas. In RA, it is especially useful in patients who do not respond to TNF-alpha inhibitors. (C) Trastuzumab – HER2/neu +ve Breast Carcinoma: This is correct because trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in HER2-positive breast cancer. It inhibits tumor growth and enhances immune-mediated destruction of cancer cells, making it a key treatment for HER2-positive breast cancer.",
      "correct_choice_id": 201755,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26483941700148785/26483941700148785.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26483941700148785/26483941700148785.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72681,
      "choices": [
        {
          "id": 201756,
          "text": "Cyclosporine"
        },
        {
          "id": 201757,
          "text": "Cytarabine"
        },
        {
          "id": 201758,
          "text": "Azathioprine"
        },
        {
          "id": 201759,
          "text": "Steroids"
        }
      ],
      "text": "All of the following are used as immunosuppressive drugs except:",
      "unique_key": "Q8472151",
      "question_audio": null,
      "question_video": null,
      "map_id": 34903238,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Cytarabine, because it is not primarily used as an immunosuppressive drug. Cytarabine (also called cytosine arabinoside or Ara-C) is a pyrimidine analog that works by inhibiting DNA polymerase, leading to DNA chain termination and cell cycle arrest in the S-phase. It is mainly used as a chemotherapeutic agent in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and lymphomas. While it does have effects on the immune system due to bone marrow suppression, it is not classified as an immunosuppressant. Incorrect Options: (A) Cyclosporine: This is incorrect because cyclosporine is a potent immunosuppressive agent that works by inhibiting calcineurin, leading to reduced IL-2 production and T-cell activation suppression. It is commonly used in organ transplantation, autoimmune diseases (e.g., rheumatoid arthritis, psoriasis), and graft-versus-host disease. (C) Azathioprine: This is incorrect because azathioprine is an immunosuppressant prodrug that gets converted to 6-mercaptopurine (6-MP), which inhibits purine synthesis, leading to reduced lymphocyte proliferation. It is widely used in organ transplantation, inflammatory bowel disease, and autoimmune disorders. (D) Steroids: This is incorrect because corticosteroids (such as prednisone and dexamethasone) have strong immunosuppressive and anti-inflammatory effects. They work by inhibiting cytokine production, reducing T-cell activation, and suppressing inflammatory responses. Steroids are used for autoimmune diseases, transplant rejection prevention, and allergic reactions.",
      "correct_choice_id": 201757,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70060371700148795/70060371700148795.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70060371700148795/70060371700148795.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72682,
      "choices": [
        {
          "id": 201760,
          "text": "It is a macrolide antibiotic"
        },
        {
          "id": 201761,
          "text": "It is indicated for the prophylaxis of organ transplant rejection"
        },
        {
          "id": 201762,
          "text": "Glucose intolerance is a well recognized side effect"
        },
        {
          "id": 201763,
          "text": "It can be safely administered with any nephrotoxic drug"
        }
      ],
      "text": "Which of the following statements is NOT TRUE about Tacrolimus?",
      "unique_key": "Q6568608",
      "question_audio": null,
      "question_video": null,
      "map_id": 34718174,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) It can be safely administered with any nephrotoxic drug, because tacrolimus is nephrotoxic and co-administration with other nephrotoxic drugs can significantly increase the risk of kidney damage. Tacrolimus is a calcineurin inhibitor used to suppress the immune system, mainly in organ transplantation. However, it has dose-dependent nephrotoxicity, which can lead to acute and chronic kidney injury. Drugs like aminoglycosides, NSAIDs, amphotericin B, and cyclosporine can potentiate nephrotoxicity when used with tacrolimus, so it should not be combined indiscriminately with nephrotoxic agents. Incorrect Options: (A) It is a macrolide antibiotic: This is correct because tacrolimus is structurally related to macrolide antibiotics, though it does not have antibacterial properties. It was originally derived from Streptomyces tsukubaensis and belongs to the macrolide immunosuppressant group, similar to cyclosporine. (B) It is indicated for the prophylaxis of organ transplant rejection: This is correct because tacrolimus is widely used to prevent organ rejection in kidney, liver, and heart transplants. It works by inhibiting calcineurin, which leads to suppression of T-cell activation and IL-2 production. (C) Glucose intolerance is a well-recognized side effect: This is correct because tacrolimus can cause hyperglycemia and diabetes due to its effect on pancreatic beta cells and insulin secretion. This side effect is particularly significant in transplant patients, leading to new-onset diabetes after transplantation (NODAT).",
      "correct_choice_id": 201763,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10741101700148805/10741101700148805.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10741101700148805/10741101700148805.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72683,
      "choices": [
        {
          "id": 201764,
          "text": "It is a prodrug"
        },
        {
          "id": 201765,
          "text": "It is a selective, uncompetitive and reversible inhibitor of IMP dehydrogenase"
        },
        {
          "id": 201766,
          "text": "It inhibits calcineurin"
        },
        {
          "id": 201767,
          "text": "Selectively inhibits lymphocytic proliferation"
        }
      ],
      "text": "One of the following statements regarding mycophenolate mofetil is INCORRECT:",
      "unique_key": "Q4234407",
      "question_audio": null,
      "question_video": null,
      "map_id": 34879080,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) It inhibits calcineurin, because mycophenolate mofetil (MMF) does not inhibit calcineurin. Instead, it works by inhibiting inosine monophosphate dehydrogenase (IMPDH), which is crucial for purine synthesis in lymphocytes. By blocking IMPDH, MMF prevents the proliferation of B and T lymphocytes. In contrast, calcineurin inhibitors like cyclosporine and tacrolimus suppress immune function by inhibiting IL-2 production, which is essential for T-cell activation. Since MMF does not interfere with calcineurin signaling, this statement is incorrect. Incorrect Options: (A) It is a prodrug: This is correct because mycophenolate mofetil is a prodrug that gets converted to its active form, mycophenolic acid (MPA), after absorption. The prodrug form enhances bioavailability and gastrointestinal absorption. (B) It is a selective, uncompetitive, and reversible inhibitor of IMP dehydrogenase: This is correct because MMF selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. This inhibition depletes guanosine nucleotides, which are critical for lymphocyte proliferation, making it an effective immunosuppressant. (D) Selectively inhibits lymphocytic proliferation: This is correct because MMF primarily targets lymphocyte proliferation, as B and T lymphocytes rely on de novo purine synthesis for replication, unlike other cells that can use the salvage pathway. This selective action makes MMF particularly effective in preventing organ rejection without widespread myelosuppression.",
      "correct_choice_id": 201766,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33575431700148817/33575431700148817.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33575431700148817/33575431700148817.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72684,
      "choices": [
        {
          "id": 201768,
          "text": "Nephrotoxicity"
        },
        {
          "id": 201769,
          "text": "Neurotoxicity"
        },
        {
          "id": 201770,
          "text": "Hirsutism"
        },
        {
          "id": 201771,
          "text": "Hyperglycemia"
        }
      ],
      "text": "All of the following are the adverse effects of Tacrolimus except:",
      "unique_key": "Q2022417",
      "question_audio": null,
      "question_video": null,
      "map_id": 34536193,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Hirsutism, because tacrolimus does not cause hirsutism. Instead, hirsutism (excessive hair growth) is a well-known side effect of cyclosporine, another calcineurin inhibitor. Tacrolimus, on the other hand, is more commonly associated with alopecia (hair loss) rather than hirsutism. Incorrect Options: (A) Nephrotoxicity: This is correct because tacrolimus is highly nephrotoxic. It can cause renal vasoconstriction, leading to acute kidney injury and chronic interstitial nephropathy. This is why renal function needs to be closely monitored in patients receiving tacrolimus. (B) Neurotoxicity: This is correct because tacrolimus is associated with neurotoxic effects, such as tremors, headaches, insomnia, seizures, and encephalopathy. These symptoms are dose-dependent and more common at higher blood levels of tacrolimus. (D) Hyperglycemia: This is correct because tacrolimus can cause glucose intolerance and new-onset diabetes after transplantation (NODAT). It does this by reducing insulin secretion from pancreatic beta cells and inducing insulin resistance, leading to hyperglycemia in transplant recipients.",
      "correct_choice_id": 201770,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72557101700148840/72557101700148840.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72557101700148840/72557101700148840.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72685,
      "choices": [
        {
          "id": 201772,
          "text": "Imiquimod"
        },
        {
          "id": 201773,
          "text": "Podophylline"
        },
        {
          "id": 201774,
          "text": "Interferon alpha"
        },
        {
          "id": 201775,
          "text": "Acyclovir"
        }
      ],
      "text": "Topical immunomodulator used for the treatment of genital warts is:",
      "unique_key": "Q4484833",
      "question_audio": null,
      "question_video": null,
      "map_id": 34020939,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Imiquimod, because imiquimod is a topical immunomodulator used in the treatment of genital warts caused by human papillomavirus (HPV). It works by activating the immune system through Toll-like receptor 7 (TLR-7), stimulating the production of cytokines such as interferon-alpha, tumor necrosis factor-alpha, and interleukins (IL-6, IL-12). This enhances the body's ability to fight HPV and clear the warts. Imiquimod is applied topically and is particularly useful for external genital and perianal warts. Incorrect Options: (B) Podophylline: While podophylline is used to treat genital warts, it is not an immunomodulator. Instead, it acts by inhibiting microtubule formation, leading to cell cycle arrest and necrosis of wart tissue. However, it has potential cytotoxicity and systemic absorption issues, limiting its use. (C) Interferon alpha: Though interferon-alpha has antiviral and immunomodulatory properties, it is not used topically for genital warts. It is usually administered via injections for systemic viral infections and certain cancers. (D) Acyclovir: Acyclovir is an antiviral drug used primarily for herpes simplex virus (HSV) infections. It is not effective against HPV and therefore not used for genital warts.",
      "correct_choice_id": 201772,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52481411700148862/52481411700148862.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52481411700148862/52481411700148862.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72686,
      "choices": [
        {
          "id": 201776,
          "text": "Systemic lupus erythematosus"
        },
        {
          "id": 201777,
          "text": "Seronegative arthritis"
        },
        {
          "id": 201778,
          "text": "Psoriatic arthritis"
        },
        {
          "id": 201779,
          "text": "Crohn’s disease"
        }
      ],
      "text": "Anti-TNF alpha drugs are used for treatment of all of the following disease except:",
      "unique_key": "Q7581013",
      "question_audio": null,
      "question_video": null,
      "map_id": 34566476,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Systemic lupus erythematosus (SLE) because anti-TNF-alpha drugs are not used for the treatment of SLE. In fact, TNF-alpha inhibitors may worsen SLE or even induce a lupus-like syndrome in some patients. While TNF-alpha plays a role in autoimmune diseases, its inhibition in SLE has not shown significant benefits and can sometimes exacerbate the disease. Therefore, anti-TNF-alpha drugs are generally avoided in SLE treatment. Incorrect Options: (B) Seronegative arthritis: Anti-TNF-alpha drugs like etanercept, infliximab, and adalimumab are commonly used for seronegative spondyloarthropathies (e.g., ankylosing spondylitis, reactive arthritis). These conditions involve inflammatory arthritis without rheumatoid factor, and TNF-alpha inhibition helps reduce inflammation and prevent joint damage. (C) Psoriatic arthritis: TNF-alpha inhibitors are highly effective in psoriatic arthritis, a chronic inflammatory arthritis associated with psoriasis. These drugs help in reducing joint inflammation, preventing progression of the disease, and improving skin lesions. (D) Crohn’s disease: Anti-TNF-alpha agents (e.g., infliximab, adalimumab, certolizumab) are widely used for treating Crohn’s disease, a type of inflammatory bowel disease (IBD). These drugs help in reducing intestinal inflammation, inducing remission, and maintaining disease control in patients with moderate to severe Crohn’s disease.",
      "correct_choice_id": 201776,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75462411700148876/75462411700148876.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75462411700148876/75462411700148876.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72687,
      "choices": [
        {
          "id": 201780,
          "text": "Intravenous immunoglobulin"
        },
        {
          "id": 201781,
          "text": "Steroids"
        },
        {
          "id": 201782,
          "text": "Azathioprine"
        },
        {
          "id": 201783,
          "text": "Aspirin"
        }
      ],
      "text": "Treatment of choice for Kawasaki disease is:",
      "unique_key": "Q3771625",
      "question_audio": null,
      "question_video": null,
      "map_id": 34204556,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Intravenous immunoglobulin (IVIG) because IVIG is the treatment of choice for Kawasaki disease, a systemic vasculitis that primarily affects young children. Early administration of IVIG (preferably within the first 10 days of illness) significantly reduces the risk of coronary artery aneurysms, which is the most serious complication of Kawasaki disease. The exact mechanism of IVIG is not fully understood, but it is believed to work by modulating the immune response and reducing inflammation. A single high-dose IVIG infusion (2 g/kg) is given alongside aspirin to reduce fever and inflammation. Incorrect Options: (B) Steroids: Corticosteroids are not first-line treatment for Kawasaki disease. They may be considered in IVIG-resistant cases or in patients at high risk of coronary artery complications. However, routine use of steroids is not recommended due to concerns about potential worsening of coronary complications. (C) Azathioprine: Azathioprine is an immunosuppressant used for autoimmune diseases and organ transplantation, but it has no role in the acute treatment of Kawasaki disease. (D) Aspirin: Aspirin is an important part of Kawasaki disease treatment but is not the primary treatment choice. It is used in high doses during the acute febrile phase for its anti-inflammatory effects, and then in low doses for its antiplatelet effects to prevent thrombosis in coronary aneurysms. However, aspirin alone is not sufficient to prevent complications, making IVIG the definitive treatment.",
      "correct_choice_id": 201780,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56612201700148889/56612201700148889.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56612201700148889/56612201700148889.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72688,
      "choices": [
        {
          "id": 201784,
          "text": "Myocarditis"
        },
        {
          "id": 201785,
          "text": "Constipation"
        },
        {
          "id": 201786,
          "text": "Peripheral neuropathy"
        },
        {
          "id": 201787,
          "text": "Sedation"
        }
      ],
      "text": "All of the following are adverse effects of thalidomide except:",
      "unique_key": "Q7710492",
      "question_audio": null,
      "question_video": null,
      "map_id": 34192237,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Myocarditis. Thalidomide is an immunomodulatory and anti-angiogenic drug primarily used in the treatment of multiple myeloma and erythema nodosum leprosum. While it has several well-documented adverse effects, myocarditis is not a recognized side effect of thalidomide. Myocarditis, which refers to inflammation of the heart muscle, is typically associated with viral infections, autoimmune conditions, or certain medications, but thalidomide has not been linked to causing this condition. Explanation of Incorrect Options: (B) Constipation: Thalidomide has a well-known side effect of causing gastrointestinal issues, particularly constipation. This occurs due to its sedative properties, which can lead to reduced gut motility, slowing the passage of stool through the intestines. (C) Peripheral Neuropathy: One of the most significant adverse effects of thalidomide is peripheral neuropathy, which can manifest as numbness, tingling, or pain in the extremities. This occurs due to the drug’s neurotoxic effects, which damage peripheral nerves, and can sometimes be irreversible with prolonged use. (D) Sedation: Thalidomide was originally developed as a sedative, and its CNS depressant effects are still observed as a side effect. Patients taking thalidomide often experience drowsiness, fatigue, or dizziness, making sedation one of its prominent adverse effects.",
      "correct_choice_id": 201784,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20864261700148900/20864261700148900.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20864261700148900/20864261700148900.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72689,
      "choices": [
        {
          "id": 201788,
          "text": "SLE"
        },
        {
          "id": 201789,
          "text": "Rheumatoid arthritis"
        },
        {
          "id": 201790,
          "text": "Sjogren syndrome"
        },
        {
          "id": 201791,
          "text": "Scleroderma"
        }
      ],
      "text": "Abatacept is a new drug approved for:",
      "unique_key": "Q1486856",
      "question_audio": null,
      "question_video": null,
      "map_id": 34202383,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Rheumatoid arthritis (RA). Abatacept is a selective T-cell costimulation modulator used primarily for the treatment of rheumatoid arthritis. It is a fusion protein composed of the extracellular domain of CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) linked to the Fc portion of IgG1. Abatacept works by binding to CD80/CD86 on antigen-presenting cells, preventing their interaction with CD28 on T cells. This inhibits T-cell activation, reducing inflammation and joint damage in RA. It is particularly useful in patients with inadequate response to methotrexate or TNF inhibitors. Explanation of Incorrect Options: (A) Systemic Lupus Erythematosus (SLE): Although T-cell activation plays a role in SLE pathogenesis, abatacept is not a first-line treatment for lupus. Other biologic agents, such as belimumab (a B-cell inhibitor), are specifically approved for lupus treatment. (C) Sjögren’s Syndrome: Sjögren’s syndrome is an autoimmune disorder characterized by lymphocytic infiltration of salivary and lacrimal glands, leading to dry eyes and mouth. While abatacept has been explored in clinical trials for Sjögren’s syndrome, it is not yet an approved treatment for the condition. (D) Scleroderma: Scleroderma, or systemic sclerosis, involves fibrosis of the skin and internal organs due to excessive collagen deposition. Abatacept does not target the primary mechanisms driving fibrosis, and it is not an FDA-approved treatment for scleroderma. Current management focuses on immunosuppressants like mycophenolate mofetil and cyclophosphamide.",
      "correct_choice_id": 201789,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72769981700148911/72769981700148911.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72769981700148911/72769981700148911.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72690,
      "choices": [
        {
          "id": 201792,
          "text": "Human metapneumovirus"
        },
        {
          "id": 201793,
          "text": "Para-influenza virus type 2 and 4"
        },
        {
          "id": 201794,
          "text": "Influenza virus"
        },
        {
          "id": 201795,
          "text": "Respiratory syncytial virus"
        }
      ],
      "text": "Palivizumab, a monoclonal antibody is used for the prophylaxis of:",
      "unique_key": "Q9230394",
      "question_audio": null,
      "question_video": null,
      "map_id": 34085473,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Respiratory Syncytial Virus (RSV). Palivizumab is a monoclonal antibody specifically designed for the prevention of severe RSV infections, particularly in high-risk infants and children. It is a humanized IgG1 monoclonal antibody that targets the F (fusion) protein of RSV, preventing viral entry into host cells. Palivizumab is not a treatment for RSV but is used prophylactically in premature infants, infants with bronchopulmonary dysplasia, and those with congenital heart disease who are at higher risk for severe RSV-related complications. Explanation of Incorrect Options: (A) Human Metapneumovirus: Human metapneumovirus (hMPV) is a paramyxovirus that causes respiratory tract infections, particularly in young children and immunocompromised individuals. While it shares clinical similarities with RSV, palivizumab does not provide protection against hMPV, and there is currently no specific monoclonal antibody approved for hMPV prophylaxis. (B) Parainfluenza Virus Type 2 and 4: Parainfluenza viruses (PIVs) cause respiratory infections, including croup, bronchitis, and pneumonia. PIV types 1 and 2 are the most common causes of croup, while type 4 is associated with mild upper respiratory symptoms. Palivizumab does not neutralize PIVs, and there are no monoclonal antibodies approved for parainfluenza virus prophylaxis. (C) Influenza Virus: Influenza is caused by influenza A and B viruses and is prevented primarily through annual vaccination (inactivated or live-attenuated vaccines) and antiviral medications like oseltamivir or zanamivir for treatment. Palivizumab has no role in influenza prevention or treatment, as it is specific to RSV.",
      "correct_choice_id": 201795,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24316231700148921/24316231700148921.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24316231700148921/24316231700148921.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72691,
      "choices": [
        {
          "id": 201796,
          "text": "CD3"
        },
        {
          "id": 201797,
          "text": "CD 25"
        },
        {
          "id": 201798,
          "text": "CD 20"
        },
        {
          "id": 201799,
          "text": "CD 4"
        }
      ],
      "text": "Basiliximab is inhibitor of:",
      "unique_key": "Q1056365",
      "question_audio": null,
      "question_video": null,
      "map_id": 34999665,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) CD25. Basiliximab is a monoclonal antibody that specifically targets CD25, the α-chain of the interleukin-2 receptor (IL-2R) found on activated T lymphocytes. CD25 is highly expressed on activated T cells, which play a crucial role in immune responses, particularly in organ transplant rejection. By blocking IL-2R, basiliximab prevents T-cell activation and proliferation, thereby exerting an immunosuppressive effect. It is primarily used in the prevention of acute organ rejection in kidney transplant recipients, typically in combination with other immunosuppressants like calcineurin inhibitors and corticosteroids. Incorrect Options: (A) CD3: CD3 is a component of the T-cell receptor (TCR) complex, crucial for T-cell activation. Drugs like muromonab-CD3 (OKT3) specifically target CD3 to cause T-cell depletion. However, basiliximab does not bind to CD3, making this answer incorrect. (C) CD20: CD20 is a B-cell surface antigen targeted by drugs like rituximab, which is used for B-cell malignancies (e.g., non-Hodgkin’s lymphoma) and autoimmune diseases (e.g., rheumatoid arthritis, pemphigus vulgaris). Basiliximab does not affect B cells or CD20, so this option is incorrect. (D) CD4: CD4 is a co-receptor found on helper T cells and is involved in immune signaling. It is the primary target of HIV infection and can be modulated by investigational therapies, but basiliximab does not act on CD4. Drugs like ibalizumab, used in HIV treatment, target CD4, but basiliximab does not.",
      "correct_choice_id": 201797,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6510041700148937/6510041700148937.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6510041700148937/6510041700148937.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72692,
      "choices": [
        {
          "id": 201800,
          "text": "Palivizumab"
        },
        {
          "id": 201801,
          "text": "Ranibizumab"
        },
        {
          "id": 201802,
          "text": "Eculizumab"
        },
        {
          "id": 201803,
          "text": "Raxibacumab"
        }
      ],
      "text": "Which of the following is used to treat paroxysmal nocturnal hemoglobinuria(PNH)?",
      "unique_key": "Q3337113",
      "question_audio": null,
      "question_video": null,
      "map_id": 34001851,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Eculizumab. Eculizumab is a monoclonal antibody that inhibits complement protein C5, preventing its cleavage into C5a and C5b. This inhibition blocks the formation of the membrane attack complex (MAC), which is responsible for the destruction of red blood cells in paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, acquired hematologic disorder characterized by chronic hemolysis, thrombosis, and bone marrow failure due to the absence of protective proteins (CD55 and CD59) on red blood cells, leading to complement-mediated hemolysis. By preventing MAC formation, eculizumab significantly reduces intravascular hemolysis, hemoglobinuria, and thrombotic complications, improving patient outcomes. Explanation of Incorrect Options: (A) Palivizumab: Palivizumab is a monoclonal antibody against the RSV F (fusion) protein, used for prophylaxis of respiratory syncytial virus (RSV) infections in high-risk infants. It has no role in PNH treatment, making this option incorrect. (B) Ranibizumab: Ranibizumab is an anti-VEGF (vascular endothelial growth factor) monoclonal antibody fragment used for ocular conditions such as age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. Since PNH is a hematologic disorder and not related to VEGF, ranibizumab has no therapeutic role in PNH, making this answer incorrect. (D) Raxibacumab: Raxibacumab is a monoclonal antibody against the Bacillus anthracis protective antigen, used as an antitoxin for inhalational anthrax. It has no effect on complement-mediated hemolysis in PNH, making it an incorrect choice.",
      "correct_choice_id": 201802,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11273621700148951/11273621700148951.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11273621700148951/11273621700148951.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72693,
      "choices": [
        {
          "id": 201804,
          "text": "Prednisolone"
        },
        {
          "id": 201805,
          "text": "Mycophenolate"
        },
        {
          "id": 201806,
          "text": "Leflunomide"
        },
        {
          "id": 201807,
          "text": "Cyclophosphamide"
        }
      ],
      "text": "Which of the following immunosuppressant is longest acting?",
      "unique_key": "Q7944738",
      "question_audio": null,
      "question_video": null,
      "map_id": 34098250,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Leflunomide. Leflunomide is a disease-modifying antirheumatic drug (DMARD) that exerts its immunosuppressive effects by inhibiting dihydroorotate dehydrogenase, an enzyme essential for pyrimidine synthesis in lymphocytes. By depleting pyrimidine levels, leflunomide suppresses the proliferation of activated T and B cells, reducing immune-mediated inflammation. What makes leflunomide the longest-acting immunosuppressant is its active metabolite, teriflunomide, which has an extremely long half-life of approximately 15–18 days due to enterohepatic recirculation. This prolonged duration of action requires careful monitoring, especially in cases of toxicity, where cholestyramine can be used to accelerate drug elimination. Explanation of Incorrect Options: (A) Prednisolone: Prednisolone is a glucocorticoid that exerts its immunosuppressive effects by inhibiting inflammation, cytokine production, and immune cell activation. While effective, prednisolone has a relatively shorter duration of action compared to leflunomide, with a half-life of 2–4 hours, although its biological effects may persist longer. However, due to its rapid metabolism and lack of prolonged recirculation, it is not the longest-acting immunosuppressant. (B) Mycophenolate: Mycophenolate (mycophenolate mofetil or mycophenolate sodium) is an inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme required for guanine nucleotide synthesis in lymphocytes. It is commonly used in organ transplantation and autoimmune diseases. Although it has a longer half-life than prednisolone (about 16 hours for mycophenolic acid, its active metabolite), it is still significantly shorter than leflunomide’s half-life of 15–18 days. (D) Cyclophosphamide: Cyclophosphamide is a cytotoxic alkylating agent that cross-links DNA, leading to apoptosis of rapidly dividing immune cells. It is used in conditions such as severe autoimmune diseases and certain cancers. Despite its potent immunosuppressive effects, it has a relatively shorter half-life of 3–12 hours, depending on liver metabolism. While its immunosuppressive effects can be prolonged due to its impact on bone marrow, it does not have the same sustained drug presence as leflunomide.",
      "correct_choice_id": 201806,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58258291700148962/58258291700148962.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58258291700148962/58258291700148962.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72694,
      "choices": [
        {
          "id": 201808,
          "text": "Anti CD20 chimeric monoclonal antibody used in leukemia & lymphomas;"
        },
        {
          "id": 201809,
          "text": "Can be combined with methotrexate for RA"
        },
        {
          "id": 201810,
          "text": "Anti-rejection agent in kidney transplant"
        },
        {
          "id": 201811,
          "text": "Extremely safe and well tolerated"
        }
      ],
      "text": "Wrong about rituximab is:",
      "unique_key": "Q7916238",
      "question_audio": null,
      "question_video": null,
      "map_id": 34657902,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Extremely safe and well tolerated. While rituximab is generally well tolerated, it is not considered \"extremely safe\" because it has several serious potential adverse effects. Rituximab is associated with infusion-related reactions, which can range from mild fever and chills to severe anaphylaxis. Additionally, it increases the risk of opportunistic infections, including reactivation of hepatitis B virus (HBV), progressive multifocal leukoencephalopathy (PML) due to JC virus reactivation, and severe neutropenia. Due to these risks, patients require monitoring for infections, and HBV screening is recommended before initiation. Explanation of Incorrect Options: (A) Anti-CD20 chimeric monoclonal antibody used in leukemia & lymphomas: This statement is correct. Rituximab is a chimeric monoclonal antibody targeting CD20, a surface antigen found on B lymphocytes. It is widely used in the treatment of B-cell malignancies, including non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). By depleting B cells, rituximab effectively reduces tumor burden in these hematologic cancers. (B) Can be combined with methotrexate for RA: This statement is correct. Rituximab is approved for rheumatoid arthritis (RA) in patients who have failed TNF inhibitors. It is commonly used in combination with methotrexate to enhance efficacy, as methotrexate helps reduce B-cell repopulation after rituximab therapy. (C) Anti-rejection agent in kidney transplant: This statement is correct. Rituximab is used off-label as an anti-rejection agent in kidney transplantation, particularly in cases of antibody-mediated rejection (AMR) and desensitization protocols for highly sensitized patients. By depleting B cells, it reduces alloantibody production, making it beneficial in transplant settings.",
      "correct_choice_id": 201811,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50177971700148979/50177971700148979.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50177971700148979/50177971700148979.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72695,
      "choices": [
        {
          "id": 201812,
          "text": "Cyclosporine"
        },
        {
          "id": 201813,
          "text": "Tacrolimus"
        },
        {
          "id": 201814,
          "text": "Mycophenolate"
        },
        {
          "id": 201815,
          "text": "Thalidomide"
        }
      ],
      "text": "Hemolytic uremic syndrome risk is increased with sirolimus if it is given in combination with?",
      "unique_key": "Q5738561",
      "question_audio": null,
      "question_video": null,
      "map_id": 34515597,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Tacrolimus. Sirolimus, an mTOR inhibitor, is commonly used as an immunosuppressant in organ transplantation. However, when combined with tacrolimus (a calcineurin inhibitor, CNI), the risk of hemolytic uremic syndrome (HUS) increases significantly. Both sirolimus and tacrolimus contribute to endothelial damage, microvascular thrombosis, and nephrotoxicity, which are key factors in the development of HUS. The mechanism involves synergistic toxicity to the renal endothelium, leading to thrombotic microangiopathy (TMA), hemolysis, thrombocytopenia, and acute kidney injury (AKI). Due to this increased risk, the combination of sirolimus and tacrolimus is generally avoided in transplant recipients. Explanation of Incorrect Options: (A) Cyclosporine: Cyclosporine is another calcineurin inhibitor (CNI) that can cause nephrotoxicity and endothelial damage. However, while cyclosporine alone can contribute to thrombotic microangiopathy (TMA), the risk of HUS is generally lower than with tacrolimus + sirolimus combination. Cyclosporine and sirolimus are sometimes used together, though with caution. (C) Mycophenolate: Mycophenolate (mycophenolate mofetil or mycophenolate sodium) is an antimetabolite immunosuppressant that inhibits inosine monophosphate dehydrogenase (IMPDH), reducing purine synthesis in lymphocytes. Unlike calcineurin inhibitors, mycophenolate does not cause endothelial toxicity or thrombotic microangiopathy and is not associated with an increased risk of HUS when combined with sirolimus. (D) Thalidomide: Thalidomide is an immunomodulatory drug used in multiple myeloma and certain inflammatory conditions. It has anti-angiogenic properties but is not associated with an increased risk of HUS when used with sirolimus. While thalidomide has other toxicities (e.g., teratogenicity, peripheral neuropathy, thrombosis), it does not significantly contribute to thrombotic microangiopathy like tacrolimus does.",
      "correct_choice_id": 201813,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20728071700148992/20728071700148992.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20728071700148992/20728071700148992.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72696,
      "choices": [
        {
          "id": 201816,
          "text": "Panitumumab"
        },
        {
          "id": 201817,
          "text": "Pegatinib"
        },
        {
          "id": 201818,
          "text": "Pertuzumab"
        },
        {
          "id": 201819,
          "text": "Pembrolizumab"
        }
      ],
      "text": "Which of the following is used for cancer immunotherapy?",
      "unique_key": "Q7286815",
      "question_audio": null,
      "question_video": null,
      "map_id": 34569832,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Pembrolizumab. Pembrolizumab is a monoclonal antibody targeting PD-1 (programmed death-1) receptor, a key immune checkpoint protein expressed on T cells. By blocking PD-1, pembrolizumab prevents tumor cells from evading immune detection, thereby enhancing T-cell-mediated anti-tumor activity. It is widely used in the treatment of various cancers, including non-small cell lung cancer (NSCLC), melanoma, Hodgkin’s lymphoma, urothelial carcinoma, and head and neck squamous cell carcinoma (HNSCC). Pembrolizumab is part of immune checkpoint inhibitor (ICI) therapy, a revolutionary approach in cancer immunotherapy, significantly improving survival in patients with advanced malignancies. Explanation of Incorrect Options: (A) Panitumumab: Panitumumab is a monoclonal antibody against epidermal growth factor receptor (EGFR), used in the treatment of EGFR-expressing metastatic colorectal cancer. While it is an anti-cancer agent, it does not function as an immune checkpoint inhibitor or a direct cancer immunotherapy drug, making it an incorrect choice for this question. (B) Pegaptanib: Pegaptanib is a VEGF inhibitor used primarily for age-related macular degeneration (AMD) to reduce abnormal blood vessel growth in the retina. It has no role in cancer therapy or immunotherapy, making this option incorrect. (C) Pertuzumab: Pertuzumab is a monoclonal antibody targeting HER2 (human epidermal growth factor receptor 2), used in combination with trastuzumab and chemotherapy for HER2-positive breast cancer. While it is an effective targeted therapy for cancer, it is not considered cancer immunotherapy because it does not enhance the immune system's ability to recognize and attack tumors.",
      "correct_choice_id": 201819,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31944911700149017/31944911700149017.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31944911700149017/31944911700149017.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72697,
      "choices": [
        {
          "id": 201820,
          "text": "Associated with diarrhea"
        },
        {
          "id": 201821,
          "text": "Characterized by enantiomeric inter conversions"
        },
        {
          "id": 201822,
          "text": "Metabolized extensively by hepatic CYP system"
        },
        {
          "id": 201823,
          "text": "Safe for use in pregnant females"
        }
      ],
      "text": "Thalidomide, used for multiple myeloma, is",
      "unique_key": "Q5566282",
      "question_audio": null,
      "question_video": null,
      "map_id": 34681813,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Characterized by enantiomeric interconversions. Thalidomide is a chiral drug with R- and S-enantiomers that undergo spontaneous interconversion in physiological conditions. This means that even if a single enantiomer is administered, it will eventually convert into a mixture of both forms in the body. The R-enantiomer is responsible for sedative effects, while the S-enantiomer is teratogenic, causing severe birth defects, particularly limb malformations (phocomelia). Due to this property, isolating a single enantiomer does not eliminate its risks, making thalidomide an important but strictly regulated drug. Explanation of Incorrect Options: (A) Associated with diarrhea: This statement is incorrect because thalidomide is more commonly associated with constipation, not diarrhea. It has anti-inflammatory and immunomodulatory properties, and one of its adverse effects includes slowing of gastrointestinal motility, leading to constipation. (C) Metabolized extensively by hepatic CYP system: Thalidomide is primarily hydrolyzed non-enzymatically in plasma and tissues rather than being extensively metabolized by the hepatic cytochrome P450 (CYP) system. While minor metabolism by CYP enzymes may occur, it is not the main route of drug breakdown, making this option incorrect. (D) Safe for use in pregnant females: This statement is incorrect. Thalidomide is highly teratogenic and is strictly contraindicated in pregnancy. Its use during pregnancy in the late 1950s and early 1960s led to thousands of cases of congenital malformations, primarily limb deformities (phocomelia). Due to its severe teratogenic effects, thalidomide is now used under strict pregnancy prevention programs in conditions such as multiple myeloma and erythema nodosum leprosum (ENL).",
      "correct_choice_id": 201821,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28715131700149029/28715131700149029.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28715131700149029/28715131700149029.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72698,
      "choices": [
        {
          "id": 201824,
          "text": "Breast"
        },
        {
          "id": 201825,
          "text": "Prostate"
        },
        {
          "id": 201826,
          "text": "Kidney"
        },
        {
          "id": 201827,
          "text": "Pancreas"
        }
      ],
      "text": "Sipuleucel-T is used in the treatment of which cancer?",
      "unique_key": "Q4442683",
      "question_audio": null,
      "question_video": null,
      "map_id": 34338605,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Prostate cancer. Sipuleucel-T is an autologous cellular immunotherapy (cancer vaccine) used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a form of personalized immunotherapy that involves collecting a patient’s antigen-presenting cells (APCs), exposing them to a fusion protein containing prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), and then reinfusing them into the patient. This process activates the immune system to target and attack prostate cancer cells expressing PAP, leading to improved survival in patients with advanced prostate cancer. Explanation of Incorrect Options: (A) Breast Cancer: Breast cancer is not treated with Sipuleucel-T. Instead, breast cancer treatments commonly include hormonal therapy (tamoxifen, aromatase inhibitors), chemotherapy, targeted therapy (trastuzumab for HER2-positive breast cancer), and immune checkpoint inhibitors (e.g., pembrolizumab for triple-negative breast cancer). (C) Kidney Cancer: Kidney cancer, specifically renal cell carcinoma (RCC), is typically treated with immune checkpoint inhibitors (nivolumab, pembrolizumab), tyrosine kinase inhibitors (sunitinib, pazopanib), and mTOR inhibitors (everolimus, temsirolimus). Sipuleucel-T does not play a role in kidney cancer treatment. (D) Pancreatic Cancer: Pancreatic cancer is not treated with Sipuleucel-T. The standard treatments include chemotherapy (gemcitabine, FOLFIRINOX), targeted therapies (erlotinib for EGFR-positive cases), and in some cases, immunotherapy with pembrolizumab in microsatellite instability-high (MSI-H) tumors.",
      "correct_choice_id": 201825,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13077131700149041/13077131700149041.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13077131700149041/13077131700149041.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72699,
      "choices": [
        {
          "id": 201828,
          "text": "Rheumatoid arthritis"
        },
        {
          "id": 201829,
          "text": "Osteoporosis"
        },
        {
          "id": 201830,
          "text": "Osteoarthritis"
        },
        {
          "id": 201831,
          "text": "Systemic lupus erythematosus"
        }
      ],
      "text": "Donesumab, a monoclonal antibody against RANK ligand is used for the treatment of:",
      "unique_key": "Q4854859",
      "question_audio": null,
      "question_video": null,
      "map_id": 34794268,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Osteoporosis. Denosumab is a monoclonal antibody against RANK ligand (RANKL), which plays a crucial role in osteoclast activation and bone resorption. By inhibiting RANKL, denosumab prevents osteoclast differentiation and function, leading to decreased bone resorption and increased bone density. It is primarily used in the treatment of postmenopausal osteoporosis, osteoporosis in men, and bone loss associated with hormone therapy for breast and prostate cancer. Denosumab is particularly beneficial for patients at high risk of fractures and is administered as a subcutaneous injection every six months. Explanation of Incorrect Options: (A) Rheumatoid arthritis: Denosumab is not used for rheumatoid arthritis (RA). RA is an autoimmune disorder characterized by chronic inflammation and joint destruction. The primary treatments for RA include disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, biologics like TNF inhibitors (adalimumab, infliximab), IL-6 inhibitors (tocilizumab), and JAK inhibitors (tofacitinib). While RA patients may develop osteoporosis due to chronic inflammation and corticosteroid use, denosumab does not treat the underlying autoimmune disease. (C) Osteoarthritis: Denosumab is not indicated for osteoarthritis (OA). OA is a degenerative joint disease primarily involving cartilage breakdown rather than excessive bone resorption. The main treatments for OA include pain management (NSAIDs, acetaminophen), physical therapy, intra-articular corticosteroids, and hyaluronic acid injections. Since RANKL inhibition does not play a role in cartilage repair or OA pathology, denosumab is not used in this condition. (D) Systemic lupus erythematosus (SLE): SLE is an autoimmune disease affecting multiple organ systems, characterized by autoantibody production and immune complex deposition. The treatment involves corticosteroids, hydroxychloroquine, immunosuppressants (mycophenolate, cyclophosphamide), and biologics (belimumab, rituximab). While SLE patients are at risk of osteoporosis due to corticosteroid use, denosumab does not treat the autoimmune process of lupus, making this option incorrect.",
      "correct_choice_id": 201829,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7564281700149051/7564281700149051.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7564281700149051/7564281700149051.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72700,
      "choices": [
        {
          "id": 201832,
          "text": "Azathioprine"
        },
        {
          "id": 201833,
          "text": "Etanercept"
        },
        {
          "id": 201834,
          "text": "Cyclophosphamide"
        },
        {
          "id": 201835,
          "text": "Mycophenolate mofetil"
        }
      ],
      "text": "A 35-year-old male with rheumatoid arthritis has been treated with methotrexate and glucocorticoids but continues to experience significant joint pain and swelling. The physician decides to start a biologic immunomodulator. Which of the following agents is most likely to be considered for this patient?",
      "unique_key": "Q8164941",
      "question_audio": null,
      "question_video": null,
      "map_id": 34994832,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Etanercept. Etanercept is a biologic immunomodulator that functions as a TNF-α inhibitor. TNF-α (tumor necrosis factor-alpha) plays a crucial role in the inflammatory process of rheumatoid arthritis (RA) by promoting synovial inflammation, joint destruction, and systemic inflammation. Since the patient has not responded adequately to methotrexate and glucocorticoids, adding a biologic disease-modifying antirheumatic drug (DMARD) is an appropriate next step. Etanercept acts as a TNF receptor fusion protein, binding TNF-α and preventing its interaction with cell surface receptors, thereby reducing inflammation, joint damage, and disease progression. It is commonly used in moderate to severe RA, either alone or in combination with methotrexate. Explanation of Incorrect Options: (A) Azathioprine: Azathioprine is a purine synthesis inhibitor that suppresses lymphocyte proliferation. While it is used as an immunosuppressant in autoimmune diseases (e.g., lupus, vasculitis, inflammatory bowel disease), it is not a first-line treatment for RA and is generally less effective than TNF inhibitors for severe RA. Additionally, it has higher toxicity risks, including bone marrow suppression and hepatotoxicity. (C) Cyclophosphamide: Cyclophosphamide is an alkylating agent that causes DNA cross-linking and suppression of rapidly dividing cells, including immune cells. It is used in severe autoimmune diseases such as systemic lupus erythematosus (SLE) with nephritis, vasculitis, and other life-threatening conditions, but it is not typically used for RA due to its severe side effects, including bone marrow suppression, hemorrhagic cystitis, and increased risk of malignancies. (D) Mycophenolate mofetil (MMF): MMF is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that prevents purine synthesis in lymphocytes, leading to immunosuppression. It is commonly used in organ transplantation, lupus nephritis, and autoimmune diseases like vasculitis, but it is not a preferred treatment for RA. TNF inhibitors, such as etanercept, have better efficacy and safety profiles for RA compared to MMF.",
      "correct_choice_id": 201833,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72701,
      "choices": [
        {
          "id": 201836,
          "text": "Orlistat"
        },
        {
          "id": 201837,
          "text": "Phentermine"
        },
        {
          "id": 201838,
          "text": "Lorcaserin"
        },
        {
          "id": 201839,
          "text": "Naltrexone/bupropion"
        }
      ],
      "text": "A 42-year-old woman with a BMI of 32 kg/m² seeks advice for weight management. After lifestyle modifications, she is started on an anti-obesity drug that works by inhibiting the absorption of dietary fats. Which medication was prescribed?",
      "unique_key": "Q6601705",
      "question_audio": null,
      "question_video": null,
      "map_id": 34734383,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Orlistat. Orlistat is a lipase inhibitor that works by inhibiting gastric and pancreatic lipases, the enzymes responsible for breaking down dietary triglycerides in the intestine. By preventing the hydrolysis of fats into absorbable free fatty acids and monoglycerides, orlistat reduces fat absorption by approximately 30%, leading to decreased calorie intake and weight loss. It is indicated for weight management in obese patients (BMI ≥30 kg/m²) or overweight individuals (BMI ≥27 kg/m²) with comorbidities such as diabetes or hypertension. The most common side effects include gastrointestinal symptoms (steatorrhea, flatulence, fecal urgency), fat-soluble vitamin deficiencies (A,D,E,K), and rare cases of liver toxicity. Explanation of Incorrect Options: (B) Phentermine: Phentermine is a sympathomimetic amine that acts as an appetite suppressant by increasing norepinephrine release in the hypothalamus. It reduces hunger and food intake but does not affect fat absorption. While it is used for short-term weight loss, it is not the correct choice for this patient since the question specifies a drug that inhibits fat absorption. (C) Lorcaserin: Lorcaserin is a serotonin 5-HT2C receptor agonist that promotes satiety and reduces appetite. It was previously used for weight management but has been withdrawn from the market due to concerns about an increased risk of cancer. Additionally, lorcaserin does not inhibit fat absorption, making it an incorrect answer. (D) Naltrexone/Bupropion: This combination drug works by modulating the central reward and appetite pathways. Bupropion is a dopamine and norepinephrine reuptake inhibitor, and naltrexone is an opioid receptor antagonist; together, they reduce cravings and increase energy expenditure. However, this drug does not inhi",
      "correct_choice_id": 201836,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72702,
      "choices": [
        {
          "id": 201840,
          "text": "Mycophenolate mofetil"
        },
        {
          "id": 201841,
          "text": "Cyclophosphamide"
        },
        {
          "id": 201842,
          "text": "Azathioprine"
        },
        {
          "id": 201843,
          "text": "Rituximab"
        }
      ],
      "text": "A 28-year-old female with systemic lupus erythematosus (SLE) is experiencing frequent flares despite being on hydroxychloroquine. Her physician considers introducing a more potent immunosuppressive agent. Which of the following drugs would be most appropriate for this patient?",
      "unique_key": "Q2109898",
      "question_audio": null,
      "question_video": null,
      "map_id": 34850466,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Mycophenolate mofetil (MMF). Mycophenolate mofetil is an immunosuppressive agent that works by inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for de novo purine synthesis in lymphocytes. This results in selective inhibition of B and T cell proliferation, making it an effective treatment for moderate to severe systemic lupus erythematosus (SLE), especially lupus nephritis. It is preferred due to its better safety profile compared to cyclophosphamide and is commonly used as a steroid-sparing agent in patients who continue to have SLE flares despite hydroxychloroquine. Explanation of Incorrect Options: (B) Cyclophosphamide: Cyclophosphamide is a potent alkylating agent that suppresses rapidly dividing immune cells by cross-linking DNA. It is used in severe or life-threatening SLE cases, particularly lupus nephritis (Class III, IV, or V) and neuropsychiatric lupus. However, it has significant toxicity, including infertility, hemorrhagic cystitis, bone marrow suppression, and increased risk of malignancies. Since this patient's condition is not described as severe, cyclophosphamide would not be the first choice. (C) Azathioprine: Azathioprine is a purine analog that suppresses lymphocyte proliferation and is sometimes used for maintenance therapy in SLE. However, it is generally less potent than mycophenolate mofetil and is not as effective for active disease or lupus nephritis. It is typically reserved for milder cases or patients who cannot tolerate MMF. (D) Rituximab: Rituximab is a monoclonal antibody targeting CD20+ B cells, leading to B cell depletion. While it has been used off-label in refractory lupus, especially in SLE with severe organ involvement (such as refractory lupus nephritis or hematologic manifestations), it is not the first-line choice for escalating treatment after hydroxychloroquine failure. Mycophenolate mofetil remains the preferred option for moderate to severe SLE before considering rituximab.",
      "correct_choice_id": 201840,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72703,
      "choices": [
        {
          "id": 201844,
          "text": "Dupilumab"
        },
        {
          "id": 201845,
          "text": "Mepolizumab"
        },
        {
          "id": 201846,
          "text": "Benralizumab"
        },
        {
          "id": 201847,
          "text": "Omalizumab"
        }
      ],
      "text": "A patient with chronic rhinosinusitis with nasal polyps is prescribed a new monoclonal antibody that targets IL-4 and IL-13. What is the name of this medication?",
      "unique_key": "Q3656270",
      "question_audio": null,
      "question_video": null,
      "map_id": 34335207,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Dupilumab. Dupilumab is a monoclonal antibody that targets the IL-4 receptor α subunit (IL-4Rα), which is shared by both IL-4 and IL-13 signaling pathways. These cytokines play a crucial role in type 2 inflammation, which is associated with chronic rhinosinusitis with nasal polyps (CRSwNP), atopic dermatitis, and eosinophilic asthma. By blocking IL-4 and IL-13 signaling, dupilumab helps reduce inflammation, mucus production, and tissue remodeling, leading to improved nasal airflow and symptom relief in patients with CRSwNP. Explanation of Incorrect Options: (B) Mepolizumab: Mepolizumab is a monoclonal antibody that targets IL-5, a key cytokine involved in the survival and activation of eosinophils. It is primarily used for the treatment of eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA) but does not directly inhibit IL-4 or IL-13, making it an incorrect choice for CRSwNP. (C) Benralizumab: Benralizumab is a monoclonal antibody against IL-5 receptor α (IL-5Rα), leading to depletion of eosinophils through antibody-dependent cell-mediated cytotoxicity (ADCC). It is used for severe eosinophilic asthma, but it does not target IL-4 or IL-13, making it inappropriate for CRSwNP. (D) Omalizumab: Omalizumab is an anti-IgE monoclonal antibody used for allergic asthma and chronic spontaneous urticaria. While it has been explored for CRSwNP, it primarily modulates allergic responses rather than directly inhibiting IL-4 or IL-13, making it less suitable for type 2 inflammation-driven nasal polyps compared to dupilumab.",
      "correct_choice_id": 201844,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 72704,
      "choices": [
        {
          "id": 201848,
          "text": "Tofacitinib"
        },
        {
          "id": 201849,
          "text": "Baricitinib"
        },
        {
          "id": 201850,
          "text": "Upadacitinib"
        },
        {
          "id": 201851,
          "text": "All of the above"
        }
      ],
      "text": "A patient with moderate to severe atopic dermatitis is started on a new drug that is an oral JAK inhibitor. What is the name of this medication?",
      "unique_key": "Q2326509",
      "question_audio": null,
      "question_video": null,
      "map_id": 34037632,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Tofacitinib. Tofacitinib is an oral Janus kinase (JAK) inhibitor that primarily inhibits JAK1 and JAK3, leading to downregulation of cytokine signaling involved in inflammation. It is used for the treatment of moderate to severe atopic dermatitis (AD), rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. By blocking JAK-mediated pathways, tofacitinib helps reduce skin inflammation, itching, and barrier dysfunction, providing symptomatic relief for patients with atopic dermatitis who are not responding adequately to topical treatments or biologics. Explanation of Incorrect Options: (B) Baricitinib: Baricitinib is also a JAK inhibitor, but it primarily inhibits JAK1 and JAK2 rather than JAK3. While it has been approved for rheumatoid arthritis and COVID-19-related cytokine storm, it is not the first-choice JAK inhibitor for atopic dermatitis, making it a less appropriate option in this context. (C) Upadacitinib: Upadacitinib is another selective JAK1 inhibitor approved for rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. However, while it is effective, tofacitinib was the first JAK inhibitor explored for atopic dermatitis and is the best-recognized in this setting. (D) All of the above: While all three drugs (tofacitinib, baricitinib, and upadacitinib) belong to the JAK inhibitor class, tofacitinib is the most widely associated with atopic dermatitis treatment, making option (D) incorrect.",
      "correct_choice_id": 201848,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}